LadRx
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
11726 San Vicente Blvd Ste 650, Los Ange...Phone Number
(310) 826-5648Website
www.ladrxcorp.comRevenue
<$5 MillionStock Symbol
CX5N.BEIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About LadRx
LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.Explore more
LadRx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LadRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if LadRx has recently received funding, and reach out quickly before it becomes old news!
Click to see if LadRx had a recent Job posting/layoffs
Check out if LadRx is spiking on competitors!
Funding: Get notified immidiatlly once LadRx has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at LadRx
Earning: See what the market has to say on LadRx recently announced quarterly report
Product Launch: Get notified when LadRx launches new products
LadRx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined LadRx as Masked Content
Find 3 more new buyers
Compare Similar Companies to LadRx
Compare insights from companies similar to LadRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
LadRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LadRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LadRx.
LadRx financials insights
Gather financial insights about LadRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$40M
2023
Other Financing Round
$11M
LadRx Tech Stack
A closer look at the technologies used by LadRx
Most Recent Scoops
Facilities Relocation / Expansion
LadRx is planning to move offices in January 2024. The move will impact approximately 10 employees at the existing office located at 11726 San Vicente Blvd, Suite # 650, Los Angeles, CA.
Facilities Relocation/Expansion
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
LadRx News & Media
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under the provisions of the FDA’s Section 505(b)(2). The 505(b)(2) pathway is designed for a new drug composition whose active ingredient is the same active ingredient as a drug previously approved bLadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”), together with NantCell’s parent company ImmunityBio, Inc. (“ImmunityBio”), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCLadRx Issues 2024 Update to Shareholders
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7. *** January 9, 2024 Dear LadRx Shareholders, It was a busy close to 2023 and has already been an exciting start to 2024. We are pleased to provide the following uLadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it has transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) (“XOMA”). In exchange for the future rights to royalties and milestones on arimoclomol and aldoxorubicin, the agreement provides to LadRx $5 million in g
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LadRx
Sign Up For FreeTo access detailed company insights
LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.... Read More
